Corix Bioscience (CXBS) Stock Price

Corix Bioscience Price

NYSE·CLOSED
0.00
+0.00 (+0.00 %)
Market closed

For Corix Bioscience, the net margin of -638.6% is down versus -573.4% a few years ago.

Corix Bioscience stock price

Volume
Details

Stock Price

How to Read This Chart

This chart tracks the historical stock price of Corix Bioscience over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Corix Bioscience stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Corix Bioscience's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Corix Bioscience Stock Price History
DateCorix Bioscience Price
9/16/20260.00 USD
9/15/20260.00 USD
9/14/20260.00 USD
9/11/20260.00 USD
9/10/20260.00 USD
9/9/20260.00 USD
9/8/20260.00 USD
9/4/20260.00 USD
9/3/20260.00 USD
9/2/20260.00 USD
9/1/20260.00 USD
8/31/20260.00 USD
8/28/20260.00 USD
8/27/20260.00 USD
8/26/20260.00 USD
8/25/20260.00 USD
8/24/20260.00 USD
8/21/20260.00 USD
8/20/20260.00 USD
8/19/20260.00 USD
8/18/20260.00 USD
8/17/20260.00 USD
8/14/20260.00 USD
8/13/20260.00 USD
8/12/20260.00 USD
8/11/20260.00 USD
8/10/20260.00 USD
8/7/20260.00 USD
8/6/20260.00 USD
8/5/20260.00 USD
Access this data via the Eulerpool API

Corix Bioscience Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2009
0.00 USD
-70,000.00 USD
-80,000.00 USD
Jan 1, 2010
0.00 USD
-150,000.00 USD
-770,000.00 USD
Jan 1, 2011
0.00 USD
-66,000.00 USD
-76,300.00 USD
Jan 1, 2012
0.00 USD
-1.69 M USD
-1.70 M USD
Jan 1, 2013
0.00 USD
-11,600.00 USD
-1.72 M USD
Jan 1, 2014
0.00 USD
-54,046.00 USD
-57,153.00 USD
Jan 1, 2015
482,426.00 USD
-2.57 M USD
-2.77 M USD
Jan 1, 2016
693,621.00 USD
-3.98 M USD
-4.43 M USD

Corix Bioscience Income Statement, Balance Sheet, Cash Flow Statement

Last updated Sep 21, 2026, 5:16 PM
 
EBITM USD
NET INCOMEM USD
NET INCOME GROWTH%
SHARESk
2007200820092010201120122013201420152016
-1.00-2.00-3.00
-1.00-1.00-2.00-4.00
100.00
116.10116.10116.10116.100.100.100.10116.10116.10116.10
Details

Income Statement Key Figures

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Corix Bioscience generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Corix Bioscience retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Corix Bioscience's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Corix Bioscience has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Corix Bioscience's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Corix Bioscience stock margins

The Corix Bioscience margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Corix Bioscience. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Corix Bioscience.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2009
100.00 %
- %
- %
Jan 1, 2010
100.00 %
- %
- %
Jan 1, 2011
100.00 %
- %
- %
Jan 1, 2012
100.00 %
- %
- %
Jan 1, 2013
100.00 %
- %
- %
Jan 1, 2014
100.00 %
- %
- %
Jan 1, 2015
100.00 %
-533.14 %
-573.44 %
Jan 1, 2016
100.00 %
-573.17 %
-638.63 %

Corix Bioscience Stock Revenue, EBIT, Earnings per Share

The Corix Bioscience earnings per share therefore indicates how much revenue Corix Bioscience has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2009
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2010
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2011
0.00 USD
-660.00 USD
-763.00 USD
Jan 1, 2012
0.00 USD
-16,903.00 USD
-16,973.00 USD
Jan 1, 2013
0.00 USD
-116.00 USD
-17,216.00 USD
Jan 1, 2014
0.00 USD
-0.47 USD
-0.49 USD
Jan 1, 2015
4.16 USD
-22.15 USD
-23.83 USD
Jan 1, 2016
5.97 USD
-34.24 USD
-38.15 USD

Corix Bioscience business model & stock analysis

Corix Bioscience is a company specialized in the production of cannabinoid-based products. It was founded in 2014 under the name American Housing Income Trust, a holding company focused on the American real estate market. In 2017, the company decided to restructure and change its name to Corix Bioscience. Since then, the company has become one of the leading manufacturers of CBD oils and other cannabinoid-based products. Corix Bioscience's business model is based on state-of-the-art technologies and innovation in the cannabinoid industry. The company collaborates with other firms to develop new products tailored to patient needs. The company aims to provide patients with a natural and safe alternative to conventional medical therapy. Corix Bioscience has five divisions. These include "Corix Bioscience," which focuses on the development of CBD-based products for the European market. "Corix Health" develops cannabinoid-based products specifically tailored to patient needs. "Subsidiaries" is responsible for collaborating with other companies to expand the product offering. "Licensing" offers licenses for technologies and rights to use innovative products. "Research and Development" focuses on advancing research and technologies in the cannabinoid industry. One of Corix Bioscience's most well-known products is CBD oil. It is extracted from specially bred hemp plants and is used for pain relief, anxiety, and other ailments. The company also offers CBD-based cosmetic products and food. Corix Bioscience is headquartered in Fresno, California, and is now internationally active. The company places special emphasis on the quality of its products and uses only natural and certified ingredients. Corix Bioscience advocates for fair and sustainable production and focuses on environmental protection and sustainability. The future prospects for Corix Bioscience are promising. The company operates in a forward-thinking market, focusing on innovation and sustainability. The developments in the market for cannabinoid-based products allow Corix Bioscience to expand its portfolio and offer more patients a natural alternative to conventional medical therapy.

Corix Bioscience SWOT Analysis

Strengths

Corix Bioscience Inc. possesses several strengths that contribute to its competitive advantage:

  • Strong research and development capabilities, enabling the company to innovate and create new products.
  • Diverse product portfolio, catering to various segments of the bioscience market.
  • Established brand reputation, recognized for high-quality and reliable products.
  • Strong financial position, allowing for investments in growth opportunities.

Weaknesses

Despite its strengths, Corix Bioscience Inc. also has a number of weaknesses that may hinder its performance:

  • Relatively small market share compared to dominant competitors.
  • Dependence on a limited number of key suppliers, leading to potential supply chain disruptions.
  • Less diversified revenue streams, making the company vulnerable to market fluctuations.

Opportunities

Corix Bioscience Inc. can leverage the following opportunities to further grow and expand its business:

  • Increasing demand for bioscience solutions across various industries.
  • Growing trend towards environmentally friendly and sustainable products, aligning with the company's expertise.
  • Exploring new markets and geographic regions for expansion.
  • Potential collaborations or partnerships with research institutions or industry leaders.

Threats

Corix Bioscience Inc. should also be aware of the following threats that may impact its operations:

  • Intense competition from large, well-established players in the bioscience industry.
  • Regulatory changes and compliance requirements impacting product development and distribution.
  • Economic downturns or market instability affecting customer purchasing power.
  • Potential disruption due to emerging technologies or alternative solutions.

Corix Bioscience Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Corix Bioscience Employees
Details
Date
Corix Bioscience Employees
Jan 1, 2009
- Employees
Jan 1, 2010
- Employees
Jan 1, 2011
- Employees
Jan 1, 2012
- Employees
Jan 1, 2013
- Employees
Jan 1, 2014
- Employees
Jan 1, 2015
- Employees
Jan 1, 2016
- Employees

Corix Bioscience Eulerpool Fair Value

Details

Fair Value Estimate

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Corix Bioscience historical P/E ratio, EBIT multiple, and P/S ratio

Corix Bioscience annual returns

Details

Annual Return

What This Chart Shows

This chart breaks down Corix Bioscience's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in Corix Bioscience's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare Corix Bioscience's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Corix Bioscience shares outstanding

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2009
8.53 M Stocks
Jan 1, 2010
8.53 M Stocks
Jan 1, 2011
100.00 Stocks
Jan 1, 2012
100.00 Stocks
Jan 1, 2013
100.00 Stocks
Jan 1, 2014
116,100.00 Stocks
Jan 1, 2015
116,100.00 Stocks
Jan 1, 2016
116,100.00 Stocks

Corix Bioscience stock splits

Since 2009, a total of 0.00002580645161290323 shares have been converted from one Corix Bioscience share.

DateRatioType
6/10/20151000 : 1Reverse Stock Split
2/21/2014775 : 1Reverse Stock Split
1/30/20091 : 20Stock Split
Price targets and forecasts for Corix Bioscience are not yet available.

Corix Bioscience Beneficial Ownership Filings (SEC 13D/G)

Free Float
56.3%
Float Shares
15.39 M
Shares Outstanding
27.34 M

Frequently asked questions about Corix Bioscience

Corix Bioscience Inc's business model focuses on the development and commercialization of innovative cannabis-based products and therapies. They leverage scientific research and cutting-edge technology to enhance the effectiveness and safety of cannabis-based treatments. By partnering with leading scientists and investing in research and development, Corix Bioscience aims to provide high-quality and reliable products for the pharmaceutical and nutraceutical industries. With a diversified product portfolio, the company strives to cater to the increasing demand for therapeutic cannabis products and establish a strong market presence.

Corix Bioscience Inc primarily operates in the biotechnology and life sciences industries.

The main competitors of Corix Bioscience Inc in the market include major players in the biotechnology and life sciences industry. Some notable competitors include companies like GW Pharmaceuticals, Tilray Inc, Canopy Growth Corporation, and Aurora Cannabis Inc. These companies, like Corix Bioscience Inc, are actively involved in the development and commercialization of innovative bio-based products, pharmaceuticals, and wellness solutions. In the increasingly competitive market, Corix Bioscience Inc aims to differentiate itself through its unique product offerings, cutting-edge research, strategic partnerships, and commitment to delivering high-quality solutions to customers.

Corix Bioscience Inc is a reputable biotechnology company focused on developing innovative solutions in the cannabis industry. Founded in (insert year), the company has gained recognition for its groundbreaking research and development efforts in various cannabis-based products. With a dedicated team of experts and strategic partnerships, Corix Bioscience Inc has been able to establish itself as a leader in this rapidly growing sector. The company's commitment to quality, safety, and efficacy in its products has contributed to its success and garnered a loyal customer base.

Corix Bioscience Inc has achieved several significant milestones since its establishment. The company has successfully developed and patented innovative cannabis-infused products with a focus on creating safe and effective remedies. Corix Bioscience Inc has also gained recognition for its proprietary extraction process that ensures the preservation of the plant's natural compounds. Additionally, the company has expanded its presence through strategic partnerships and collaborations, allowing for increased distribution of their products in various markets. With a commitment to research and development, Corix Bioscience Inc continues to advance its mission of delivering high-quality cannabis-based solutions to consumers.

Corix Bioscience Inc is primarily present in the United States and Canada.

Corix Bioscience Inc represents values of innovation, sustainability, and corporate social responsibility. Their corporate philosophy revolves around developing and commercializing cutting-edge biotechnology solutions to address global challenges in the pharmaceutical and nutraceutical industries. Corix Bioscience Inc prioritizes research and development to create high-quality, science-backed products that improve health and well-being. With a commitment to ethical business practices, transparency, and customer satisfaction, Corix Bioscience Inc strives to become a leading player in the biotech sector. Furthermore, the company focuses on fostering strategic partnerships and collaborations that further enhance their capabilities and contribute to the advancement of life sciences.

Converted at the current exchange rate, the Corix Bioscience share trades at 0.00 EUR (0.00 USD).

Corix Bioscience Inc is a company specializing in the development of bio and cannabis products. The business model of Corix Bioscience Inc is multifaceted and includes several divisions, with a focus on research and development, manufacturing, and distribution. Research and Development: Corix Bioscience Inc conducts intensive research and development of bio and cannabis products with the aim of developing cleaner medicine and alternative health products. In these efforts, the company focuses on the development of innovative methods for active ingredient extraction and the use of natural ingredients. Manufacturing: The company produces a wide range of products made from organically grown raw materials. In recent years, Corix Bioscience Inc has invested in the growth and processing of cannabis, hemp, and other organic products. These products are manufactured in laboratories and production facilities that are subject to strict controls to ensure full compliance with safety regulations and laws. Another pillar in the manufacturing sector involves the production of CBD oils and extracts. The focus here is on natural and high-quality products that offer customers good and balanced benefits. Distribution: Corix Bioscience Inc distributes its products through various channels, including wholesalers, online retailers, retail stores, and direct sales outlets. The sales strategies are designed to ensure addressing different target groups. Clear positioning and offering the right products ensure successful business. Products: Corix Bioscience Inc distributes a wide range of bio and cannabinoid products. The range includes CBD oil, CBD tincture (also in alcohol), CBD capsules, CBD cosmetics, hemp seeds, hemp oil, and hemp oil capsules. Various lotions, oils, and creams based on natural ingredients are offered in the cosmetics sector. Conclusion: Corix Bioscience Inc has successfully established itself in the market. By investing in research and development, as well as in the production and distribution of bio and cannabis products, the company has been able to develop a diverse range of products. Corix Bioscience Inc places special emphasis on natural products and innovation. As a result, it has gained a loyal customer base that is enthusiastic about the products. In the future, Corix Bioscience Inc should align its strategies towards the future in order to continue to be a commercial success.

The revenue cannot currently be calculated for Corix Bioscience.

The profit cannot currently be calculated for Corix Bioscience.

The P/E ratio cannot be calculated for Corix Bioscience at the moment.

The P/S cannot be calculated for Corix Bioscience currently.

The Eulerpool Quality Score for Corix Bioscience is 3/10.

The ISIN of Corix Bioscience is US21887N1037. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Corix Bioscience is A14UX1. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Corix Bioscience is CXBS. The ticker symbol is used to trade Corix Bioscience shares on the stock exchange.

Corix Bioscience paid dividends every year for the past 0 years.

Corix Bioscience is assigned to the 'Health' sector.

The dividends of Corix Bioscience are distributed in USD.

Fair ValuePRO
0.00 USD
Over-/UndervaluationPRO
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website ahitrust.com
Currency
USD
Initial public offering
Apr 8, 2009
ISIN
US21887N1037
Cusip
21887N103
Sedol
BF7MQC7
Market capitalization
52-Week Range
0.000.00USD
Revenue growth (10Y) > 5%
Revenue growth (3Y) > 5 %
EBIT growth (10Y) > 5%
EBIT growth (3Y) > 5 %
Net debt < 4x EBIT
Profitable since 10Y+
EBIT Drawdown (10Y) < 50%
Return on Equity (ROE) > 15%
ROCE > 15%
Return Expectation > 10%
PEG
P/E ratio
P/Ee
P/S
P/Se
EV/EBIT
P/B Ratio
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-98.97 %
Gross Margin
100.00 %
EBIT Margin
-573.17 %
Net Margin
-638.63 %
EPS (Earnings Per Share)
-38.15 USD
Net Debt / EBIT
0.00
Debt/Equity
0.00
Last updated Sep 21, 2026, 5:16 PM

Corix Bioscience FIGI

CXBS:US · BBG000C8KTC9CXBS:PQ · BBG000C8L0Y7CXBS:UV · BBG000C8L1P5